- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
home:publications:waterhouse_new_research_2006 [10.24.2009] 127.0.0.1 external edit |
home:publications:waterhouse_new_research_2006 [12.02.2009] paulalbert |
||
|---|---|---|---|
| Line 6: | Line 6: | ||
| **Publication:** //Vitamin D: New Research//\\ | **Publication:** //Vitamin D: New Research//\\ | ||
| **Citation:** Waterhouse, J. et al. High levels of active 1,25-dihydroxyvitamin D despite low levels of the 25-hydroxyvitamin D precursor — implications of dysregulated vitamin D for diagnosis and treatment of chronic disease. //Vitamin D: New Research// 1-23(2006).\\ | **Citation:** Waterhouse, J. et al. High levels of active 1,25-dihydroxyvitamin D despite low levels of the 25-hydroxyvitamin D precursor — implications of dysregulated vitamin D for diagnosis and treatment of chronic disease. //Vitamin D: New Research// 1-23(2006).\\ | ||
| - | **See also:** [[https://www.novapublishers.com/catalog/product_info.php?products_id=5380|full text available for purchase from Nova Publishers]] | + | **See also:** [[https://www.novapublishers.com/catalog/product_info.php?products_id=5380|full text available for purchase from Nova Publishers]]; [[http://books.google.com/books?id=oSl8VY33634C&pg=PA1#v=onepage&q=&f=false|most/all of chapter available as scanned document at Google Books]] |
| Line 15: | Line 15: | ||
| {{tag>book_chapters Trevor_Marshall_PhD Joyce_Waterhouse_PhD Belinda_Fenter Meg_Mangin_RN Dr._Greg_Blaney 2006 vitamin_d}} | {{tag>book_chapters Trevor_Marshall_PhD Joyce_Waterhouse_PhD Belinda_Fenter Meg_Mangin_RN Dr._Greg_Blaney 2006 vitamin_d}} | ||
| - | |||
home/publications/waterhouse_new_research_2006.txt · Last modified: 01.03.2012 (external edit)
© 2015, Autoimmunity Research Foundation. All Rights Reserved.